MX2018002885A - Sales de inhibidor de pim cinasa. - Google Patents

Sales de inhibidor de pim cinasa.

Info

Publication number
MX2018002885A
MX2018002885A MX2018002885A MX2018002885A MX2018002885A MX 2018002885 A MX2018002885 A MX 2018002885A MX 2018002885 A MX2018002885 A MX 2018002885A MX 2018002885 A MX2018002885 A MX 2018002885A MX 2018002885 A MX2018002885 A MX 2018002885A
Authority
MX
Mexico
Prior art keywords
pim kinase
kinase inhibitor
salts
hydroxy
preparation
Prior art date
Application number
MX2018002885A
Other languages
English (en)
Inventor
Qiao Lei
Zhou Jiacheng
Cao Ganfeng
Lin Qiyan
Xia Michael
Pan Yongchun
Li Qun
Jia Zhongjiang
Eric Shi Chongsheng
Sharief Vaqar
Zheng Changsheng
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MX2018002885A publication Critical patent/MX2018002885A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a formas de sal del inhibidor de Pim cinasa N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hidroxi-5-metilpiperidi n-1-il]-7-hidroxi-6,7-dihidro-5H-ciclopenta[b]piridin-3-il}-6-(2, 6-difluorofenil)-5-fluoropiridina-2-carboxamida, que incluye los métodos de preparación de estos y los intermediarios en su preparación, donde el compuesto es útil en el tratamiento de las enfermedades relacionadas con Pim cinasa tales como cáncer.
MX2018002885A 2015-09-09 2016-09-09 Sales de inhibidor de pim cinasa. MX2018002885A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562216045P 2015-09-09 2015-09-09
US201562244933P 2015-10-22 2015-10-22
PCT/US2016/050925 WO2017044730A1 (en) 2015-09-09 2016-09-09 Salts of a pim kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2018002885A true MX2018002885A (es) 2018-09-18

Family

ID=56985689

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018002885A MX2018002885A (es) 2015-09-09 2016-09-09 Sales de inhibidor de pim cinasa.
MX2021015824A MX2021015824A (es) 2015-09-09 2018-03-07 Sales de inhibidor de pim cinasa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021015824A MX2021015824A (es) 2015-09-09 2018-03-07 Sales de inhibidor de pim cinasa.

Country Status (24)

Country Link
US (5) US9862705B2 (es)
EP (1) EP3347351B1 (es)
JP (1) JP6943844B2 (es)
KR (1) KR20180067531A (es)
CN (2) CN114380798A (es)
AR (1) AR105967A1 (es)
AU (2) AU2016320892C1 (es)
CA (1) CA2997768A1 (es)
CL (3) CL2018000611A1 (es)
CO (1) CO2018003739A2 (es)
EA (1) EA201890663A1 (es)
EC (1) ECSP18026386A (es)
ES (1) ES2914686T3 (es)
HK (1) HK1256806A1 (es)
IL (2) IL257897B2 (es)
MA (1) MA42780A (es)
MX (2) MX2018002885A (es)
MY (2) MY187993A (es)
PE (1) PE20181337A1 (es)
PH (1) PH12018500511A1 (es)
SG (1) SG10201912287XA (es)
TW (1) TWI734699B (es)
WO (1) WO2017044730A1 (es)
ZA (1) ZA201802267B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102403306B1 (ko) 2013-01-15 2022-06-02 인사이트 홀딩스 코포레이션 Pim 키나제 저해제로서 유용한 티아졸카복스아마이드 및 피리딘카복스아마이드 화합물
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
EP3967307A1 (en) 2020-09-15 2022-03-16 Instytut Hematologii I Transfuzologii Use of pim kinase inhibitors to augment the efficacy of anti-cd20 antibody-based therapies in hematologic malignancies and non-malignant conditions

Family Cites Families (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1294358E (pt) 2000-06-28 2004-12-31 Smithkline Beecham Plc Processo de moagem por via humida
WO2002055489A2 (en) 2000-12-27 2002-07-18 Univ Columbia Pim kinase-related methods
KR100888093B1 (ko) * 2001-03-30 2009-03-11 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 약제학적 활성 화합물 및 이의 사용 방법
DE10123055A1 (de) 2001-05-11 2003-03-20 Gruenenthal Gmbh Screeningverfahren mit PIM1-Kinase oder PIM3-Kinase
DE10226702A1 (de) 2002-06-14 2004-09-09 Grünenthal GmbH Antisense Oligonukleotide gegen PIM1
CA2503905A1 (en) 2002-09-16 2004-03-25 Plexxikon, Inc. Crystal structure of pim-1 kinase
WO2006078228A1 (en) 2002-09-16 2006-07-27 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
WO2004090106A2 (en) 2003-04-04 2004-10-21 Vertex Pharmaceuticals Incorporated Crystal structures of human pim-1 kinase protein complexes and binding pockets thereof, and uses thereof in drug design
US20050164300A1 (en) 2003-09-15 2005-07-28 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
WO2005033310A1 (de) 2003-10-01 2005-04-14 Grünenthal GmbH Pim-1-spezifische dsrna-verbindungen
WO2006006569A1 (ja) 2004-07-12 2006-01-19 Nihon Nohyaku Co., Ltd. フェニルピリジン類又はその塩類、これらを有効成分とする除草剤及びその使用方法
BRPI0519424B8 (pt) 2004-12-28 2021-05-25 Athenex Inc compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
PL1893612T3 (pl) 2005-06-22 2012-01-31 Plexxikon Inc Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
DE602005010421D1 (de) * 2005-08-05 2008-11-27 Hybrigenics Sa Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen
WO2007044724A2 (en) 2005-10-06 2007-04-19 Exelixis, Inc. Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3
US7776865B2 (en) 2005-10-06 2010-08-17 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US8101625B2 (en) 2005-10-21 2012-01-24 Exelixis, Inc. Pyrimidinones as Casein Kinase II (CK2) modulators
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
WO2007084857A2 (en) 2006-01-13 2007-07-26 President And Fellows Of Harvard College Methods and compositions for treating cell proliferative disorders
US20090253156A1 (en) 2006-05-05 2009-10-08 Perkinelmer Las, Inc. Mass spectrometry methods for multiplexed quantification of protein kinases and phosphatases
WO2008002676A2 (en) 2006-06-29 2008-01-03 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
CN101595084B (zh) 2006-06-29 2013-01-02 金克斯医药品有限公司 用于调整激酶级联的二芳基组合物和方法
US8318723B2 (en) 2006-08-16 2012-11-27 Boehringer Ingelheim International Gmbh Pyrazine compounds, their use and methods of preparation
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
CA2668255A1 (en) 2006-10-31 2008-05-08 Schering Corporation Anilinopiperazine derivatives and methods of use thereof
KR101546493B1 (ko) 2006-11-06 2015-08-21 톨레로 파마수티컬스, 인크. 이미다조[1,2-ｂ]피리다진 및 피라졸로[1,5-ａ]피리미딘 유도체 및 단백질 키나제 억제제로서의 이의 용도
WO2008082840A1 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
CA2679659C (en) 2007-03-01 2016-01-19 Novartis Ag Pim kinase inhibitors and methods of their use
CN101679422A (zh) 2007-03-28 2010-03-24 阵列生物制药公司 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物
UA101611C2 (ru) 2007-04-03 2013-04-25 Аррей Байофарма Инк. СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ
MX2009011578A (es) 2007-04-25 2009-11-11 Exelixis Inc 6-fenilpirimidinonas como moduladores de pim.
MX2009011579A (es) 2007-04-25 2009-11-11 Exelixis Inc Pirimidinonas como moduladores de caseina cinasa ii (ck2).
AR067585A1 (es) 2007-07-19 2009-10-14 Schering Corp Compuestos heterociclicos de amidas como inhibidores de la proteincinasa
BRPI0814874A2 (pt) 2007-07-31 2019-09-24 Schering Corp combinação de agente antimitótico e inibidor da aurora quinase como tratamento anticâncer.
AR067813A1 (es) * 2007-08-06 2009-10-21 Janssen Pharmaceutica Nv Fenilendiaminas sustituidas como inhibidores de l ainteraccion entre mdm2 y p53
CA2743756A1 (en) 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibitors of pim protein kinases, compositions, and methods for treating cancer
US8617534B2 (en) 2007-11-16 2013-12-31 San Diego State University (Sdsu) Foundation Compositions and method for manipulating PIM-1 activity in circulatory system cells
CA2716755A1 (en) 2008-02-29 2009-09-03 Peter C. Chua Protein kinase modulators
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
UY31679A1 (es) 2008-03-03 2009-09-30 Inhibidores de cinasa pim y metodos para su uso
US20110294789A1 (en) 2008-05-12 2011-12-01 Amnestix, Inc. Compounds for rho kinase inhibition and for improving learning and memory
AU2009267048A1 (en) 2008-06-30 2010-01-07 Cylene Pharmaceuticals, Inc. Oxindole compounds
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
FR2933409B1 (fr) 2008-07-03 2010-08-27 Centre Nat Rech Scient NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之***吡啶化合物
WO2010022081A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
AU2009289316A1 (en) 2008-09-02 2010-03-11 Novartis Ag Bicyclic kinase inhibitors
AU2009289317A1 (en) 2008-09-02 2010-03-11 Novartis Ag Heterocyclic PIM-kinase inhibitors
PL2344474T3 (pl) 2008-09-02 2016-03-31 Novartis Ag Pochodne pikolinamidu jako inhibitory kinaz
HUE057625T2 (hu) 2008-10-22 2022-05-28 Array Biopharma Inc TRK kináz inhibitor szubsztituált pirazolo[1,5-a]pirimidin vegyületek
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
ES2539620T3 (es) 2008-12-19 2015-07-02 Cephalon, Inc. Pirrolotriazina como inhibidor de ALK y de JAK2
EP3026052A1 (en) * 2009-04-20 2016-06-01 Auspex Pharmaceuticals, Inc. Preparation of deuterated piperidine inhibitors of janus kinase 3
WO2010135401A2 (en) 2009-05-19 2010-11-25 San Diego State University Foundation Kinase-mediated cytoprotection and enhanced cellular engraftment and persistence
BRPI1011066A2 (pt) 2009-05-20 2017-03-21 Cylene Pharmaceuticals Inc "pirazolopirimidinas e heterociclos relacionados como inibidores de quinase
US20100298302A1 (en) 2009-05-20 2010-11-25 Fabrice Pierre Novel protein kinase modulators
US8716303B2 (en) 2009-05-22 2014-05-06 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US20100331315A1 (en) 2009-06-18 2010-12-30 Mustapha Haddach Rhodanines and related heterocycles as kinase inhibitors
AU2010273816B2 (en) 2009-06-29 2015-07-09 Incyte Holdings Corporation Pyrimidinones as PI3K inhibitors
US20110065698A1 (en) 2009-08-26 2011-03-17 Cylene Pharmaceuticals, Inc. Novel protein kinase modulators
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
SG178986A1 (en) 2009-09-08 2012-04-27 Hoffmann La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
US8435976B2 (en) 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
US20110071115A1 (en) 2009-09-11 2011-03-24 Cylene Pharmaceuticals, Inc. Pharmaceutically useful heterocycle-substituted lactams
JP2013505253A (ja) 2009-09-16 2013-02-14 サイリーン ファーマシューティカルズ インコーポレーティッド 三環式化合物およびその薬学的使用
WO2011035019A1 (en) 2009-09-16 2011-03-24 Cylene Pharmaceuticals, Inc. Novel tricyclic protein kinase modulators
SG10201407012XA (en) 2009-10-29 2014-11-27 Genosco Kinase inhibitors
EP2332917B1 (en) 2009-11-11 2012-08-01 Sygnis Bioscience GmbH & Co. KG Compounds for PIM kinase inhibition and for treating malignancy
RU2012120784A (ru) 2009-11-12 2013-12-20 Селвита С.А. Соединение, способ его получения, фармацевтическая композиция, применение соединения, способ модулирования или регулирования сериновых/треониновых киназ и средство, модулирующее сериновые/треониновые киназы
CN102811619B (zh) 2009-11-13 2015-04-22 金纳斯克公司 激酶抑制剂
WO2011063398A1 (en) 2009-11-23 2011-05-26 Cylene Pharamaceuticals, Inc. Polymorphs and salts of a kinase inhibitor
ES2629170T3 (es) 2009-12-04 2017-08-07 Senhwa Biosciences, Inc. Pirazolopirimidinas y heterociclos relacionados como inhibidores de CK2
WO2011075630A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
WO2011075613A1 (en) 2009-12-18 2011-06-23 Sanofi Azaindole derivatives, their preparation and their therapeutic application
US8563539B2 (en) 2009-12-23 2013-10-22 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
GB201002861D0 (en) 2010-02-19 2010-04-07 Cxr Biosciences Ltd Compositions
KR102354472B1 (ko) 2010-03-10 2022-01-21 인사이트 홀딩스 코포레이션 Ｊａｋ１ 저해제로서의 피페리딘­４­일 아제티딘 유도체
MA34234B1 (fr) 2010-04-07 2013-05-02 Hoffmann La Roche Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
US20130109682A1 (en) 2010-07-06 2013-05-02 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
CA2802641C (en) 2010-07-13 2019-03-12 Nidhi Arora Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators
US8227773B2 (en) 2010-07-29 2012-07-24 Axcelis Technologies, Inc. Versatile beam glitch detection system
MY165584A (en) 2010-07-29 2018-04-05 Rigel Pharmaceuticals Inc Ampk-activating heterocyclic compounds and methods for using the same
US8802099B2 (en) 2010-11-10 2014-08-12 National Jewish Health Methods to treat allergic conditions
WO2012065297A1 (en) 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
WO2012068450A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012078777A1 (en) 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
CN103298816A (zh) 2010-12-17 2013-09-11 内尔维阿诺医学科学有限公司 作为激酶抑制剂的取代的吡唑并-喹唑啉衍生物
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
EP2668188B1 (en) 2011-01-26 2016-05-18 Nerviano Medical Sciences S.r.l. Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
RU2591191C2 (ru) 2011-01-26 2016-07-10 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы
AU2012254082B2 (en) 2011-02-25 2016-12-08 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
CN103429572A (zh) 2011-03-04 2013-12-04 诺瓦提斯公司 作为激酶抑制剂的四取代的环己基化合物
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
EP2688886A1 (en) 2011-03-22 2014-01-29 Amgen Inc. Azole compounds as pim inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR20130133905A (ko) 2011-04-05 2013-12-09 화이자 리미티드 트로포미오신-관련 키나제의 억제제인 피롤로[2,3-d]피리미딘 유도체
WO2012139930A1 (en) 2011-04-11 2012-10-18 Nerviano Medical Sciences S.R.L. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
WO2012145617A2 (en) 2011-04-22 2012-10-26 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
GB201107197D0 (en) 2011-04-28 2011-06-15 Cxr Biosciences Ltd Compounds
GB201107176D0 (en) 2011-04-28 2011-06-15 Cxr Biosciences Ltd Pyrrolnitrin derivatives
WO2012148775A1 (en) 2011-04-29 2012-11-01 Amgen Inc. Bicyclic pyridazine compounds as pim inhibitors
EP2710004A1 (en) 2011-05-17 2014-03-26 Bayer Intellectual Property GmbH Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
PT2710018T (pt) 2011-05-19 2022-03-01 Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio Compostos macrocíclicos como inibidores de proteína quinases
AU2012262489A1 (en) 2011-05-27 2013-04-04 Icahn School Of Medicine At Mount Sinai Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof
JP6073868B2 (ja) 2011-06-01 2017-02-01 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換アミノイミダゾピリダジン
WO2012170827A2 (en) 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
JP5876146B2 (ja) 2011-06-20 2016-03-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのアゼチジニルフェニル、ピリジル、またはピラジニルカルボキサミド誘導体
WO2012175591A1 (en) 2011-06-22 2012-12-27 Bayer Intellectual Property Gmbh Heterocyclyl aminoimidazopyridazines
WO2013013188A1 (en) 2011-07-21 2013-01-24 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
CN102924445B (zh) 2011-08-11 2015-07-08 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
CA2838784A1 (en) 2011-08-12 2013-02-21 F. Hoffmann-La Roche Ag Pyrazolo[3,4-c]pyridine compounds and methods of use
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
JP5843524B2 (ja) 2011-09-02 2016-01-13 キヤノン株式会社 有機無機複合組成物、有機無機複合材料、光学素子および積層型回折光学素子
AR087760A1 (es) * 2011-09-02 2014-04-16 Incyte Corp Heterociclilaminas como inhibidores de pi3k
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US8735528B1 (en) * 2011-09-20 2014-05-27 The United States Of America As Represented By The Secretary Of The Air Force Two-photon absorbing cross-linked polyurethanes containing diphenylamino-dialkylfluorene-1,3,5-triazine units
CA2849345A1 (en) 2011-09-23 2013-03-28 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
SG2014012579A (en) 2011-09-27 2014-04-28 Hoffmann La Roche Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
US9145418B2 (en) 2011-10-07 2015-09-29 Nerviano Medical Sciences S.R.L. Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors
US9181258B2 (en) 2011-10-07 2015-11-10 Nerviano Medical Sciences S.R.L. Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors
KR101990605B1 (ko) 2011-11-04 2019-06-18 자스코 파머수티컬스, 엘엘씨 아미노피리미딘 키나아제 억제제
US9394297B2 (en) 2012-02-28 2016-07-19 Amgen Inc. Amides as pim inhibitors
US9340549B2 (en) 2012-03-05 2016-05-17 Amgen Inc. Oxazolidinone compounds and derivatives thereof
CN104487440B (zh) 2012-03-29 2016-11-23 拜耳知识产权有限责任公司 氨基取代的咪唑并哒嗪
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
ES2660981T3 (es) 2012-04-04 2018-03-26 Bayer Pharma Aktiengesellschaft Imidazopiridazinas sustituidas con amino
CN104583218B (zh) 2012-04-26 2018-04-24 百时美施贵宝公司 作为蛋白酶活化受体4(par4)抑制剂用于治疗血小板聚集的咪唑并噻二唑和咪唑并吡嗪的衍生物
WO2013160873A1 (en) 2012-04-27 2013-10-31 Novartis Ag Cyclic bridgehead ether dgat1 inhibitors
RS60424B1 (sr) 2012-05-09 2020-07-31 Biogen Ma Inc Modulatori nukleusnog transporta i njihove upotrebe
DK2861579T5 (da) 2012-05-15 2022-10-24 Novartis Ag Benzamidderivater til at hæmme aktiviteten af ABL1, ABL2 og BCR-ABL1
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
BR112014028954A2 (pt) 2012-05-21 2017-07-18 Novartis Ag amidas de n-piridinila substituídas no anel como inibidores da quinase
NZ702744A (en) 2012-05-22 2016-12-23 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之***酮化合物
KR20150028999A (ko) 2012-06-27 2015-03-17 에프. 호프만-라 로슈 아게 5-아자인다졸 화합물 및 이의 사용 방법
AR092348A1 (es) 2012-07-11 2015-04-15 Hoffmann La Roche DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
WO2014022752A1 (en) 2012-08-03 2014-02-06 Amgen Inc. Macrocycles as pim inhibitors
WO2014033631A1 (en) 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
WO2014033630A1 (en) 2012-08-31 2014-03-06 Novartis Ag Novel aminothiazole carboxamides as kinase inhibitors
CN103664878A (zh) 2012-09-12 2014-03-26 山东亨利医药科技有限责任公司 杂芳环及其衍生物类酪氨酸激酶抑制剂
IN2015DN02070A (es) 2012-09-14 2015-08-14 Abbvie Deutschland
EP2900657B1 (en) 2012-09-26 2020-03-11 F.Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
WO2014053568A1 (en) 2012-10-02 2014-04-10 Sanofi Indolyldihydroimidazopyrimidinone derivatives, preparation thereof and therapeutic use thereof
PT2909195T (pt) 2012-10-16 2017-09-13 Janssen Sciences Ireland Uc Compostos antivirais de vsr
SG10201703533VA (en) 2012-11-01 2017-06-29 Incyte Corp Tricyclic fused thiophene derivatives as jak inhibitors
EP2920176B1 (en) 2012-11-19 2017-09-13 Bayer Pharma Aktiengesellschaft Aminoimidazopyridazines as mknk1 kinase inhibitors
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
BR112015012454B1 (pt) 2012-12-07 2022-07-05 Vertex Pharmaceuticals Incorporated Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos
DK2935302T3 (en) 2012-12-18 2018-08-13 Vertex Pharma MANNOS DERIVATIVES FOR TREATING BACTERIAL INFECTIONS
US20150336960A1 (en) 2012-12-19 2015-11-26 Novartis Ag Aryl-substituted fused bicyclic pyridazine compounds
KR20150095888A (ko) 2012-12-19 2015-08-21 노파르티스 아게 오토탁신 억제제
JP6678455B2 (ja) 2012-12-21 2020-04-08 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
CN111303152B (zh) 2012-12-21 2023-04-11 吉利德科学公司 多环-氨基甲酰基吡啶酮化合物及其药物用途
FR3000569B1 (fr) 2013-01-03 2015-02-13 Peugeot Citroen Automobiles Sa Dispositif d'eclairage a ecran a bord(s) lumineux
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
KR102403306B1 (ko) 2013-01-15 2022-06-02 인사이트 홀딩스 코포레이션 Pim 키나제 저해제로서 유용한 티아졸카복스아마이드 및 피리딘카복스아마이드 화합물
TWI736135B (zh) 2013-03-01 2021-08-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
PE20151902A1 (es) 2013-03-06 2015-12-26 Incyte Corp Proceso e intermedios para hacer un inhibidor de jak
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
US9227985B2 (en) 2013-03-15 2016-01-05 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
SI2970236T1 (sl) 2013-03-15 2017-11-30 Idorsia Pharmaceuticals Ltd Derivati piridil-4-ila
LT2970265T (lt) 2013-03-15 2018-09-25 Plexxikon Inc. Heterocikliniai junginiai ir jų panaudojimas
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
AR095443A1 (es) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
AU2014237348C1 (en) 2013-03-15 2019-02-07 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014139145A1 (en) 2013-03-15 2014-09-18 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and usage thereof
TWI689489B (zh) 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
US20140275108A1 (en) 2013-03-15 2014-09-18 Galderma Research & Development Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
KR20150132146A (ko) 2013-03-15 2015-11-25 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
BR112015022077A2 (pt) 2013-03-15 2017-07-18 Japan Tobacco Inc composto de pirazol-amida e usos medicinais do mesmo
UY35421A (es) 2013-03-15 2014-10-31 Nihon Nohyaku Co Ltd Compuesto heterocíclico condensado o su sal, insecticida agrícola u hortícola que comprende el comp uesto y método de uso del insecticida
CN110583663A (zh) 2013-03-15 2019-12-20 美国陶氏益农公司 式(i)化合物及其作为除草剂的用途
JO3279B1 (ar) 2013-03-15 2018-09-16 Respivert Ltd مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
TWI689490B (zh) 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
EP3721873A1 (en) 2013-08-07 2020-10-14 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
PL3110409T3 (pl) 2014-02-28 2018-12-31 Incyte Corporation Inhibitory jak1 do leczenia zespołów mielodysplastycznych
UA119767C2 (uk) 2014-04-08 2019-08-12 Інсайт Корпорейшн Лікування b-клітинних злоякісних новоутворень із застосуванням комбінації інгібіторів jak та pi3k
TW201625643A (zh) 2014-04-30 2016-07-16 英塞特公司 製備ｊａｋ１抑制劑之方法及其新形式
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物

Also Published As

Publication number Publication date
KR20180067531A (ko) 2018-06-20
BR112018004596A2 (pt) 2018-09-25
IL257897A (en) 2018-06-03
AR105967A1 (es) 2017-11-29
TWI734699B (zh) 2021-08-01
JP2018532713A (ja) 2018-11-08
IL306054A (en) 2023-11-01
ECSP18026386A (es) 2018-07-31
AU2016320892A1 (en) 2018-04-26
AU2021203351A1 (en) 2021-06-24
CO2018003739A2 (es) 2018-08-31
CL2018000611A1 (es) 2018-07-20
US11066387B2 (en) 2021-07-20
US20170121310A1 (en) 2017-05-04
HK1256806A1 (zh) 2019-10-04
EA201890663A1 (ru) 2018-10-31
EP3347351B1 (en) 2022-03-30
MA42780A (fr) 2018-07-18
PE20181337A1 (es) 2018-08-21
CL2019002078A1 (es) 2019-12-27
MX2021015824A (es) 2022-04-01
US9862705B2 (en) 2018-01-09
CA2997768A1 (en) 2017-03-16
MY196185A (en) 2023-03-21
US10336728B2 (en) 2019-07-02
AU2016320892A8 (en) 2021-03-11
IL257897B1 (en) 2023-10-01
SG10201912287XA (en) 2020-02-27
AU2021203351B2 (en) 2022-04-21
CL2019002079A1 (es) 2019-10-18
PH12018500511A1 (en) 2018-09-03
US20190270725A1 (en) 2019-09-05
WO2017044730A1 (en) 2017-03-16
AU2016320892B2 (en) 2021-03-11
US20230111912A1 (en) 2023-04-13
IL257897B2 (en) 2024-02-01
AU2016320892C1 (en) 2022-08-11
CN114380798A (zh) 2022-04-22
MY187993A (en) 2021-11-08
US20180170907A1 (en) 2018-06-21
ES2914686T3 (es) 2022-06-15
CN108349938A (zh) 2018-07-31
US20210155605A1 (en) 2021-05-27
US11505540B2 (en) 2022-11-22
TW201722927A (zh) 2017-07-01
EP3347351A1 (en) 2018-07-18
JP6943844B2 (ja) 2021-10-06
ZA201802267B (en) 2022-10-26

Similar Documents

Publication Publication Date Title
MY196185A (en) Salts of a Pim Kinase Inhibitor
PH12018500792A1 (en) Benzolactam compounds as protein kinase inhibitors
MX2022002579A (es) Compuestos de aminotiazol como inhibidores de c- kit.
PH12018500828A1 (en) Jak kinase inhibitor compounds for treatment of respiratory disease
PH12017502050A1 (en) Naphthyridine compounds as jak kinase inhibitors
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2017004234A (es) Inhibidor del egfr y preparacion y aplicacion del mismo.
MX2018013191A (es) Compuestos de pirimidina como inhibidores de la quinasa jak.
PH12015501965B1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
NZ718728A (en) Compound inhibiting activities of btk and/or jak3 kinases
PH12020500528A1 (en) Pyrimidine compound as jak kinase inhibitor
MY169029A (en) Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
MY192861A (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
PH12016500735A1 (en) Substituted pyrimidine compounds and their use as syk inhibitors
MX2018004879A (es) Nuevos derivados de piridona y su uso como inhibidores de quinasas.
MY193381A (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors